Anna Kupryjaniuk

Anna Kupryjaniuk

Auto-generated profile, based on publicly available information

Anna Kupryjaniuk


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2022 in Frontiers in Neurology
Verified
Journal Article
Open access
MSMichał Sobstyl
Michał Sobstyl
AKAnna Kupryjaniuk
Anna Kupryjaniuk
MPMarek Prokopienko
Marek Prokopienko
MRMarcin Rylski
Marcin Rylski
Background: Deep brain stimulation (DBS) is considered a relatively new and still experimental therapeutic modality for treatment-resistant depression (TRD). There is clinical evidence to suggest that stimulation of the subcallosal cingulate cortex (SCC) involved in the pathogenesis of TRD may exert an antidepressant effect. Aims: To conduct a systematic review of current studies, such as randomized clinical trials (RCTs), open-label trials, and placebo-controlled trials, examining SCC DBS for TRD in human participants. Method: A formal review of the academic literature was performed using the Medical Literature, Analysis, and Retrieval System Online (MEDLINE) and Cochrane Central Register of Controlled Trials (CENTRAL) databases. This systematic review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Suitable studies were screened and assessed based on patient characteristics, clinical outcomes, adverse events related to DBS, and the stereotactic technique used to guide the implantation of DBS electrodes. Results: The literature search identified 14 clinical studies that enrolled a total of 230 patients with TRD who underwent SCC DBS. The average duration of follow-up was 14 months (range 6–24 months). The response and remission rates at the last available follow-up visit ranged between 23–92% and 27–66.7%, respectively. Conclusion: The current results of SCC DBS are limited by the relatively small number of patients treated worldwide. Nevertheless, studies to date suggest that SCC can be a promising and efficacious target for DBS, considering the high response and remission rates among patients with TRD. The adverse events of SCC DBS are usually transient and stimulation-induced.

25 September 2019 in British Journal Of Neurosurgery
Verified
Journal Article
Closed access
MSMichał Sobstyl
Michał Sobstyl
ASAngelika Stapińska-Syniec
Angelika Stapińska-Syniec
MSMarlena Sokół-Szawłowska
Marlena Sokół-Szawłowska
AKAnna Kupryjaniuk
Anna Kupryjaniuk
Anorexia nervosa (AN) is a challenging multifactorial disorder with the highest mortality rate among all psychiatric disorders. Due to the low rate of long-term treatment success, new treatment options are needed. Here, we review Deep Brain Stimulation (DBS) as a treatment of Severe Intractable AN. The mechanisms of AN have shown significant involvement of the central nervous system especially the same brain regions which are involved with obsessive–compulsive disorder (OCD) and major depressive disorder (MDD). AN and OCD display many similarities in psychiatric practice such as compulsive behaviours and anxiety levels, which are related to networks in the brain, that can be altered using DBS. Our literature search revealed 8 studies totalling 28 individuals with AN and comorbid OCD or MDD. The most common stereotactic targets included the sub-callosal cingulate cortex (Brodmann area 25)/medial forebrain bundle (MFB) for AN and comorbid MDD and nucleus accumbens (NAc)/ventral striatum for AN and comorbid OCD. In most cases bilateral DBS of various structures of the reward system achieved good results in BMI, and core AN symptoms and psychiatric comorbidities showed sustained improvement. DBS is a promising treatment modality for AN and comorbid OCD or MDD. These results highlight promise and hope for patients with AN. However, further studies with larger patient populations are needed to shed light on the long-term outcomes of DBS and its effects in AN treatment.

1 December 2019 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
MSMichael Sobstyl
Michael Sobstyl
ASAngelika Stapińska-Syniec
Angelika Stapińska-Syniec
JGJakub Giziński
Jakub Giziński
TKTomasz Kmieć
Tomasz Kmieć
AKAnna Kupryjaniuk
Anna Kupryjaniuk

29 October 2021 in Neurologia i Neurochirurgia Polska
Verified
Journal Article
Closed access
PDF file
MSMichał Sobstyl
Michał Sobstyl
AKAnna Kupryjaniuk
Anna Kupryjaniuk
PMPaweł Mierzejewski
Paweł Mierzejewski
Deep brain stimulation (DBS) has achieved substantial success as a treatment for movement disorders such as Parkinson’s Disease (PD), essential tremor (ET), and dystonia. More recently, a limited number of basic and clinical studies have indicated that DBS of the nucleus accumbens (NAc) and other neighbouring structures of the reward circuit may be an effective intervention for patients with treatment-refractory addiction. We performed a structured literature review of human studies of DBS for addiction outlining the clinical efficacy and adverse events. We found 14 human studies targeting mostly the NAc with neighbouring structures such as anterior limb of the internal capsule (ALIC). Five studies including 12 patients reported the outcomes for alcohol dependence. Nine studies including 18 patients reported the outcomes for addictions to various psychoactive substances. The most common indication was addiction to heroin, found in 13 patients, followed by methamphetamine, 3 patients, cocaine, one patient, and polysubstance drug abuse in one patient. The limited clinical data available indicates that DBS may be a promising therapeutic modality for the treatment of intractable addiction. In general, the safety profile of DBS in patients with addiction is good. Based on the data published in the literature, the NAc is the most often targeted, and is probably the most effective, structure of the reward circuit in the treatment of addiction in humans. Given the ever-expanding understanding of the psychosurgery of addiction, DBS could in the future be a treatment option for patients suffering from intractable addictive disorders. Deep brain stimulation (DBS) has achieved substantial success as a treatment for movement disorders such as Parkinson’s Disease (PD), essential tremor (ET), and dystonia. More recently, a limited number of basic and clinical studies have indicated that DBS of the nucleus accumbens (NAc) and other neighbouring structures of the reward circuit may be an effective intervention for patients with treatment-refractory addiction. We performed a structured literature review of human studies of DBS for addiction outlining the clinical efficacy and adverse events. We found 14 human studies targeting mostly the NAc with neighbouring structures such as anterior limb of the internal capsule (ALIC). Five studies including 12 patients reported the outcomes for alcohol dependence. Nine studies including 18 patients reported the outcomes for addictions to various psychoactive substances. The most common indication was addiction to heroin, found in 13 patients, followed by methamphetamine, 3 patients, cocaine, one patient, and polysubstance drug abuse in one patient. The limited clinical data available indicates that DBS may be a promising therapeutic modality for the treatment of intractable addiction. In general, the safety profile of DBS in patients with addiction is good. Based on the data published in the literature, the NAc is the most often targeted, and is probably the most effective, structure of the reward circuit in the treatment of addiction in humans. Given the ever-expanding understanding of the psychosurgery of addiction, DBS could in the future be a treatment option for patients suffering from intractable addictive disorders.

31 October 2022 in Psychiatria Polska
Verified
Journal Article
Open access
MSMichael Sobstyl
Michael Sobstyl
AKAnna Kupryjaniuk
Anna Kupryjaniuk
MSMarta Stajszczak
Marta Stajszczak
TPTadeusz Pietras
Tadeusz Pietras
ŁSŁukasz Swiecicki
Łukasz Swiecicki
Aim of the study: The aim of this review is to present the overview of DBS outcomes for OCD. Moreover, we have discussed the current OCD pathophysiology with its implications for DBS. We have also presented the current indications and contraindications for DBS in OCD patients as well as still...